A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms
详细信息 查看全文
- 作者：David S. Baldwina ; b ; D.S.Baldwin@soton.ac.uk" class="auth_mail" title="E-mail the corresponding author ; Ioana Floreac ; Paula L. Jacobsend ; Wei Zhongd ; George G. Nomikosd
- 关键词：5-HT ; serotonin ; AE ; adverse event ; ANCOVA ; analysis of covariance ; CGI-I ; Clinical Global Impressions&ndash ; Improvement ; CGI-S ; Clinical Global Impressions&ndash ; Severity of Illness ; DUL ; duloxetine ; EU ; European Union ; FAS ; full analysis set ; GAD ; generalized anxiety disorder ; HAM-A ; Hamilton Anxiety Rating Scale ; HAM-D ; Hamilton Depression Rating Scale ; LOCF ; last observation carried forward ; LS ; least squares ; MADRS ; Montgomery-Å ; sberg Depression Rating Scale ; MDD ; major depressive diso
- 刊名：Journal of Affective Disorders
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：206
- 期：Complete
- 页码：140-150
- 全文大小：1798 K
文摘
- •
Vortioxetine 5–20 mg efficacy and safety were evaluated in MDD patients with high anxiety.
- •
High levels of anxiety symptoms defined as HAM-A total score ≥20 at baseline.
- •
Vortioxetine reduced depression severity in MDD patients with high anxiety.
- •
Vortioxetine reduced anxiety severity in MDD patients with high anxiety.
- •
Vortioxetine was not associated with anxiogenic effects in MDD patients with high anxiety.